259 related articles for article (PubMed ID: 25143028)
1. Pericytes: a double-edged sword in cancer therapy.
Meng MB; Zaorsky NG; Deng L; Wang HH; Chao J; Zhao LJ; Yuan ZY; Ping W
Future Oncol; 2015; 11(1):169-79. PubMed ID: 25143028
[TBL] [Abstract][Full Text] [Related]
2. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
[TBL] [Abstract][Full Text] [Related]
5. PDGF and vessel maturation.
Hellberg C; Ostman A; Heldin CH
Recent Results Cancer Res; 2010; 180():103-14. PubMed ID: 20033380
[TBL] [Abstract][Full Text] [Related]
6. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
Sato Y
Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
[TBL] [Abstract][Full Text] [Related]
7. PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy.
Yin L; He J; Xue J; Na F; Tong R; Wang J; Gao H; Tang F; Mo X; Deng L; Lu Y
Biomed Pharmacother; 2018 Mar; 99():615-621. PubMed ID: 29653486
[TBL] [Abstract][Full Text] [Related]
8. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D
J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920
[TBL] [Abstract][Full Text] [Related]
9. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies of cancer: angiogenesis inhibition seems not enough.
Roodink I; Leenders WP
Cancer Lett; 2010 Dec; 299(1):1-10. PubMed ID: 20889254
[TBL] [Abstract][Full Text] [Related]
11. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
[TBL] [Abstract][Full Text] [Related]
12. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
13. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
Franco M; Pàez-Ribes M; Cortez E; Casanovas O; Pietras K
Horm Metab Res; 2011 Nov; 43(12):884-9. PubMed ID: 21960459
[TBL] [Abstract][Full Text] [Related]
14. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
15. Vascular normalization: a real benefit?
Ribatti D
Cancer Chemother Pharmacol; 2011 Aug; 68(2):275-8. PubMed ID: 21638121
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
Kunnakkat S; Mathew M; Narayana A
Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
[TBL] [Abstract][Full Text] [Related]
17. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
[TBL] [Abstract][Full Text] [Related]
18. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
[TBL] [Abstract][Full Text] [Related]
19. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
Fenton BM; Paoni SF
Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
[TBL] [Abstract][Full Text] [Related]
20. The great escape; the hallmarks of resistance to antiangiogenic therapy.
van Beijnum JR; Nowak-Sliwinska P; Huijbers EJ; Thijssen VL; Griffioen AW
Pharmacol Rev; 2015; 67(2):441-61. PubMed ID: 25769965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
